Exelixis (NASDAQ:EXEL - Get Free Report)'s stock had its "buy" rating restated by research analysts at Guggenheim in a note issued to investors on Wednesday,Benzinga reports. They currently have a $42.00 price target on the biotechnology company's stock. Guggenheim's price objective would indicate a potential upside of 20.00% from the stock's current price.
EXEL has been the topic of several other research reports. Brookline Capital Management initiated coverage on Exelixis in a research note on Monday, December 23rd. They issued a "buy" rating on the stock. TD Cowen raised their price target on Exelixis from $27.00 to $34.00 and gave the company a "buy" rating in a report on Monday, October 21st. JMP Securities reaffirmed a "market outperform" rating and issued a $41.00 price objective on shares of Exelixis in a research note on Thursday, January 23rd. UBS Group raised their price target on Exelixis from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. Finally, Bank of America lowered Exelixis from a "buy" rating to a "neutral" rating and raised their price target for the stock from $35.00 to $39.00 in a research note on Tuesday, December 17th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $37.24.
Check Out Our Latest Report on Exelixis
Exelixis Stock Performance
Shares of EXEL stock traded up $0.51 during trading hours on Wednesday, hitting $35.00. 2,854,977 shares of the company were exchanged, compared to its average volume of 2,601,778. The company has a 50 day simple moving average of $34.19 and a two-hundred day simple moving average of $30.88. Exelixis has a fifty-two week low of $20.14 and a fifty-two week high of $37.59. The firm has a market cap of $10.00 billion, a P/E ratio of 22.44, a P/E/G ratio of 0.63 and a beta of 0.53.
Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 20.99% and a net margin of 22.43%. As a group, sell-side analysts expect that Exelixis will post 1.74 EPS for the current fiscal year.
Insider Buying and Selling at Exelixis
In related news, EVP Patrick J. Haley sold 10,000 shares of the company's stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $35.27, for a total value of $352,700.00. Following the completion of the transaction, the executive vice president now owns 278,665 shares of the company's stock, valued at approximately $9,828,514.55. This represents a 3.46 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the company's stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the sale, the executive vice president now owns 486,059 shares in the company, valued at $17,823,783.53. This represents a 10.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 111,588 shares of company stock worth $3,981,864 over the last 90 days. Corporate insiders own 2.85% of the company's stock.
Institutional Trading of Exelixis
A number of institutional investors and hedge funds have recently modified their holdings of EXEL. Coppell Advisory Solutions LLC acquired a new position in Exelixis in the 4th quarter valued at about $25,000. V Square Quantitative Management LLC purchased a new stake in shares of Exelixis in the 3rd quarter valued at approximately $30,000. USA Financial Formulas purchased a new position in shares of Exelixis in the 4th quarter valued at $32,000. Principal Securities Inc. grew its position in shares of Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after buying an additional 373 shares during the last quarter. Finally, Kestra Investment Management LLC acquired a new stake in shares of Exelixis in the 4th quarter worth $39,000. Hedge funds and other institutional investors own 85.27% of the company's stock.
About Exelixis
(
Get Free Report)
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Further Reading
Before you consider Exelixis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.
While Exelixis currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
